Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-07-20 M&A Activity
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Dechra Pharmaceuticals PLC - Special resolution passed at the General Meeting 20 July 2023
M&A Activity Classification · 100% confidence The document is a formal record of a 'Special Resolution' passed at a general meeting of Dechra Pharmaceuticals PLC. The content details the adoption of a new article of association (Article 154) specifically to facilitate a 'Scheme of Arrangement' with 'Freya Bidco Limited'. This is a classic M&A document detailing the legal mechanics of a takeover bid and the resulting changes to the company's articles to accommodate the acquisition. Therefore, it falls under M&A Activity.
2023-07-20 English
Form 8.3 - Dechra Pharmaceuticals PLC
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code'. This form is used to disclose interests and dealings in securities during a takeover offer. This type of disclosure, related to insider/significant shareholder activity during a corporate action (takeover), does not fit neatly into the standard periodic reports (10-K, IR) or general announcements (ER, DIV). It is a specific regulatory filing related to a potential or ongoing takeover bid concerning Dechra Pharmaceuticals PLC. Since there is no specific code for 'Takeover Disclosure' or 'Insider Dealing' that perfectly matches the context of a Rule 8.3 filing, and given that it is a mandatory disclosure related to a corporate action, the most appropriate general category for specific, non-standard regulatory disclosures is 'Regulatory Filings' (RNS), although it is highly specific. However, upon reviewing the definitions, 'Director's Dealing' (DIRS) covers personal share transactions by executives, and while this is a major shareholder/fund manager, the context is specifically a takeover. Given the options, 'RNS' (Regulatory Filings) is the best fit for a mandatory, specific disclosure form like Form 8.3 that isn't covered by the other specific codes like 10-K, ER, or DEF 14A.
2023-07-20 English
Results of Court Meeting and General Meeting
M&A Activity Classification · 98% confidence The document is an RNS announcement (indicated by 'RNS Number : 6891G') dated 20 July 2023. The content explicitly discusses a 'RECOMMENDED CASH ACQUISITION' of Dechra Pharmaceuticals PLC by Freya Bidco Limited, implemented via a 'scheme of arrangement under Part 26 of the Companies Act 2006'. Crucially, it reports the 'Results of Court Meeting and General Meeting' related to this acquisition, including detailed voting tallies. This subject matter—a takeover bid and the subsequent shareholder/court approvals required for its implementation—falls squarely under the category of Merger/Takeover Activity. The definition for M&A Activity (Code: TAR) covers 'Announcements and documents related to merger proposals or takeover bids.' Although it is an RNS announcement, the core subject is M&A, making TAR a more specific classification than the general RNS fallback.
2023-07-20 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider transactions or significant ownership changes during a takeover scenario. Among the provided categories, 'Director's Dealing (DIRS)' covers personal share transactions by executives, and while this is a specific type of insider disclosure related to a takeover, the core activity described is the disclosure of interests and dealings by a major shareholder/stakeholder during an offer period. Since there is no specific code for 'Takeover Disclosure Form 8.3', the closest fit that captures insider/significant shareholder transaction reporting is 'Director's Dealing (DIRS)', although it is broader than just directors. However, given the context of dealing disclosures, DIRS is the most appropriate category for reporting personal security interests/dealings by involved parties during a corporate action like a takeover, as opposed to general regulatory filings (RNS) or M&A activity (TAR) which usually cover the transaction itself, not the individual disclosure form.
2023-07-19 English
Form 8.3 - Dechra Pharmaceuticals Plc
Director's Dealing Classification · 92% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals Plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of director/insider dealings or major shareholding notifications, but the specific context of the Takeover Code disclosure makes it highly specific. Since there is no direct category for 'Takeover Code Disclosure', I must choose the closest fit. 'Director's Dealing (DIRS)' covers personal share transactions by executives, and 'Major Shareholding Notification (MRQ)' covers changes in significant ownership. Given the context is a mandatory disclosure related to a potential takeover (implied by the reference to the Takeover Code and dealing disclosures), it is most closely related to insider activity or significant ownership changes. Rule 8.3 disclosures are mandatory for parties involved in a takeover. While it involves dealing, it is a specific regulatory filing related to ownership thresholds during an offer. 'DIRS' (Director's Dealing) is the closest fit for reporting personal transactions by interested parties, even if the context is a takeover, as it reports ownership and dealings. However, 'MRQ' (Major Shareholding Notification) is also relevant as it reports crossing ownership thresholds. Since this form specifically details the position and dealings of a major shareholder (Farallon Capital Europe LLP) in relation to an offer, and it is a mandatory regulatory disclosure, 'DIRS' is often used for executive/director trades, while this is a major shareholder disclosure. Given the options, 'DIRS' captures the essence of reporting personal/controlled security interests and dealings, which is the core function of this form in the context of insider activity during a bid. If 'DIRS' is interpreted strictly as only directors, then 'MRQ' (Major Shareholding Notification) is a strong alternative for reporting significant ownership changes. Since the discloser is an investment manager (Farallon) disclosing a 2.77% interest and a dealing, 'MRQ' is arguably a better fit for reporting a major shareholder's position change than 'DIRS' which is typically for company officers. However, Form 8.3 is fundamentally about disclosing interests/dealings during a takeover. Let's re-evaluate the definitions. DIRS is 'Report of personal share transactions by company directors and executives (insider trades)'. MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds)'. Since this is a mandatory disclosure under the Takeover Code, it is a specific regulatory filing. Given the content is about ownership percentage (2.77%) and dealings by a major investor, MRQ is a strong candidate. But Form 8.3 is a specific type of insider disclosure. I will classify this as DIRS as it covers insider dealings/interests during a corporate action, which is the closest functional match among the provided options for reporting security interests and transactions by an involved party.
2023-07-19 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and contains the header "PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" under "Rule 8.3 of the Takeover Code (the “Code”)". This form is a mandatory disclosure required under UK takeover regulations when a party involved in a takeover (offeror or offeree) acquires or deals in relevant securities. This type of disclosure relates to insider dealings or significant position changes during a takeover scenario. While it involves director/insider activity, the specific context of the Takeover Code (Rule 8.3) makes it distinct from general Director's Dealing (DIRS) or standard M&A activity (TAR). Since there is no specific code for 'Takeover Disclosure', and it details personal share transactions by an entity with significant interest during a potential takeover event concerning the offeree company, it most closely aligns with insider trading/dealing disclosures. However, given the provided options, 'Director's Dealing' (DIRS) is the closest fit for reporting personal share transactions by executives/insiders, even though this is a specific regulatory form (Form 8.3) related to a takeover. If 'Takeover Disclosure' were an option, it would be preferred. Given the choices, DIRS captures the essence of reporting personal security interests/dealings by an interested party, which is the core function of Form 8.3 in this context, although it is highly specific to takeover rules.
2023-07-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.